Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast Cancer
We showed here that directed complement activation on tumor cells is an alternative to therapeutic antibodies for future combination therapies upon resistance to standard-of-care treatment.
Authors
- Carole Seguin‐Devaux (ORCID: https://orcid.org/0000-0003-0636-5222)
- Jean-Yves Servais
- Rafaëla Schober (ORCID: https://orcid.org/0000-0002-9851-328X)
- Bianca Brandus
- Xavier Dervillez (ORCID: https://orcid.org/0000-0003-1321-0368)
- Iris Behrmann (ORCID: https://orcid.org/0000-0003-3688-3645)
- J. Cohen (ORCID: https://orcid.org/0000-0003-4214-4419)
- Jacques Zimmer (ORCID: https://orcid.org/0000-0002-7118-6944)
- Gilles Iserentant
- Jean‐Marc Plesséria
- Georgia Kanli (ORCID: https://orcid.org/0000-0001-8713-9838)
- Aubin Pitiot
Institutions
- University of Luxembourg (LU)
- Luxembourg Institute of Health (LU)
- Laboratoire de Recherche en Nanosciences
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-09-01
- DOI
- https://doi.org/10.2147/itt.s517584
- Citations
- 2
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 2.72